ALETA 002
Alternative Names: ALETA-002Latest Information Update: 20 Oct 2021
At a glance
- Originator Aleta Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; Protein replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer metastases; CNS cancer